Medical University of Graz
medunigraz.atLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
463
Active
96
Phase 3
23
Total enrollment
9,252,597
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Amoxicillin | — | — | — | — | — | 1 | |
| L-ornithine L-aspartate | — | — | — | — | — | 1 | |
| Poractant alfa (Curosurf®) - 1-minute administration | — | — | — | — | — | 1 | |
| Poractant alfa (Curosurf®) - 5-minute administration | — | — | — | — | — | 1 | |
| Cholecalciferol | — | — | — | — | 5 | ||
| Fecal microbiota transplantation | — | — | — | — | — | 1 | |
| Insect Venom | — | — | — | — | — | 2 | |
| all approved chemotherapeutic agents from second line | — | — | — | — | — | 1 | |
| Biomarker Monitoring | — | — | — | — | — | 1 |
Next readouts
- 2024-07-23
- 2025-12
- 2025-12
- 2026-03
- 2026-03-01
- 2027-03
- 2027-03
- 2028-07-01
Top conditions
- Pulmonary Hypertension16
- Type 1 Diabetes12
- Obesity9
- Type 2 Diabetes9
- Psoriasis9
- Vitamin D Deficiency8
- Liver Cirrhosis7
- Polymorphic Light Eruption6
Frequently asked questions about Medical University of Graz
- How many clinical trials does Medical University of Graz have on ClinicalTrials.gov?
- Medical University of Graz is listed as the lead sponsor on 463 clinical trials in ClinicalTrials.gov, 96 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Medical University of Graz's trials are in Phase 3?
- 23 of Medical University of Graz's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does Medical University of Graz focus on?
- Medical University of Graz's most-studied conditions on ClinicalTrials.gov are Pulmonary Hypertension, Type 1 Diabetes, Obesity, Type 2 Diabetes, Psoriasis.
- When are Medical University of Graz's next clinical trial readouts?
- Medical University of Graz has 8 upcoming primary-completion readouts tracked here; the soonest is “Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome”, expected around 2024-07-23.